Related Experiment Video
Updated: Jan 14, 2026

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
Published on: March 31, 2019
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21
Hongxiang Zhang1, Matthew R Tonini1, Lauren Catherine M Martires1
1Tango Therapeutics, Boston, MA, USA.
Abstract:
Chromosomal deletion of tumor suppressor genes often occurs in an imprecise manner, leading to co-deletion of neighboring genes. This collateral damage can create novel dependencies specific to the co-deleted context. One notable example is the dependency on PRMT5 activity in tumors with MTAP deletion, which co-occurs with CDKN2A/B loss, leading to the development of MTA-cooperative PRMT5 inhibitors. To identify additional collateral damage context/target pairs for chromosome 9p and other common loci of chromosomal deletions, we conducted a combinatorial CRISPR screen knocking out frequently co-deleted genes in combination with a focused target library. We identified the gene encoding the ribosome rescue factor PELO as synthetic lethal with the SKI complex interacting protein FOCAD, which is frequently co-deleted alongside MTAP and CDKN2A/B on chromosome 9p. A genome-wide screen in FOCAD isogenic cells further identified the ribosome rescue GTPase and PELO binding partner HBS1L as the top synthetic lethal target for FOCAD loss. Analysis of publicly available data and genetic manipulation of HBS1L using orthogonal modalities validated this interaction. HBS1L dependency in FOCAD-deleted cells was rescued by FOCAD re-expression, and FOCAD intact cells could be rendered HBS1L-dependent by FOCAD knockout, demonstrating the context specificity of this interaction. Mechanistically, HBS1L loss led to translational arrest and activated the unfolded protein response in FOCAD-deleted cells. In vivo, HBS1L deletion eliminated growth of FOCAD-deleted tumors. Here we propose a model where the FOCAD/SKI complex and HBS1L/PELO work together to resolve aberrant mRNA-induced ribosomal stalling, making the HBS1L/PELO complex an intriguing novel target for treating FOCAD-deleted tumors.
Insights
Researchers discovered that deleting the FOCAD gene creates a dependency on HBS1L in cancer cells. This finding reveals a new therapeutic target, HBS1L/PELO, for treating FOCAD-deleted tumors by addressing ribosomal stalling.
Area of Science:
- Genomics
- Cancer Biology
- Synthetic Lethality
Background:
- Chromosomal deletions in tumor suppressors often lead to co-deletion of neighboring genes, creating unique cancer dependencies.
- The MTAP deletion context, co-occurring with CDKN2A/B loss, exemplifies this, leading to PRMT5 inhibitors.
- Identifying new collateral damage contexts and targets is crucial for novel cancer therapies.
Purpose of the Study:
- To identify novel synthetic lethal interactions arising from co-deleted genes, particularly on chromosome 9p.
- To investigate the functional relationship between FOCAD loss and potential therapeutic targets.
- To explore the mechanistic basis and therapeutic potential of identified synthetic lethal pairs.
Main Methods:
- Combinatorial CRISPR screening of frequently co-deleted genes against a focused target library.
- Genome-wide screens in FOCAD isogenic cells to identify synthetic lethal partners.
- Validation using public data analysis and orthogonal genetic manipulation (e.g., HBS1L).
Main Results:
- PELO was identified as synthetic lethal with FOCAD, a gene frequently co-deleted with MTAP and CDKN2A/B.
- HBS1L, a PELO binding partner, was identified as the top synthetic lethal target for FOCAD loss.
- HBS1L dependency in FOCAD-deleted cells was context-specific and validated in vivo, where HBS1L deletion inhibited tumor growth.
- FOCAD loss led to translational arrest and unfolded protein response activation in cancer cells.
Conclusions:
- The FOCAD/SKI complex and HBS1L/PELO complex cooperate to resolve aberrant mRNA-induced ribosomal stalling.
- HBS1L/PELO represents a novel synthetic lethal target for FOCAD-deleted tumors.
- Targeting HBS1L/PELO offers a potential therapeutic strategy for specific cancer types with chromosome 9p deletions.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

